When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia.

Evangelos Papanastasiou, James M Stone, Sukhi Shergill

Journal: The British journal of psychiatry : the journal of mental science 2013;202():91-3

PMID: 23377207

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Currently available antipsychotic drugs target dopaminergic neurotransmission. Many patients do not respond fully to these treatments, and there has been considerable effort to investigate alternative targets. Here we summarise the rationale and recent evidence supporting efforts to develop glutamatergic antipsychotic drugs.

Address: Institute of Psychiatry, King's College London, Department of Psychosis Studies, De Crespigny Park, Denmark Hill, London, UK. [email protected]

DOI: 10.1192/bjp.bp.112.110999

Link outs

Free resources

Medical:

https://medlineplus.gov/schizophrenia.html

Other Literature Sources:

https://scite.ai/reports/23377207

Subscription / membership required

Full Text Sources:

MeSH Terms: Allosteric Regulation, Antipsychotic Agents, Dopamine D2 Receptor Antagonists, Excitatory Amino Acid Agents, Humans, Randomized Controlled Trials as Topic, Receptors, Glutamate, Schizophrenia, Treatment Failure